Literature DB >> 29120264

Treatment options for chorea.

H Bashir1, J Jankovic1.   

Abstract

INTRODUCTION: Chorea is defined as jerk-like movements that move randomly from one body part to another. It is due to a variety of disorders and although current symptomatic therapy is quite effective there are few etiology- or pathogenesis-targeted therapies. The aim of this review is to summarize our own experience and published evidence in the treatment of chorea. Areas covered: After evaluating current guidelines and clinical practices for chorea of all etiologies, PubMed was searched for the most recent clinical trials and reviews using the term 'chorea' cross referenced with specific drug names. Expert commentary: Inhibitors of presynaptic vesicular monoamine transporter type 2 (VMAT2) that cause striatal dopamine depletion, such as tetrabenazine, deutetrabenazine, and valbenazine, are considered the treatment of choice in patients with chorea. Some clinicians also use dopamine receptor blockers (e.g. antipsychotics) and other drugs, including anti-epileptics and anti-glutamatargics. 'Dopamine stabilizers' such as pridopidine and other experimental drugs are currently being investigated in the treatment of chorea. Deep brain stimulation is usually reserved for patients with disabling chorea despite optimal medical therapy.

Entities:  

Keywords:  Chorea; DBS; Huntington’s disease; antipsychotics; deutetrabenazine; dyskinesia; neuroleptics; tetrabenazine

Mesh:

Substances:

Year:  2017        PMID: 29120264     DOI: 10.1080/14737175.2018.1403899

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  7 in total

1.  Is Benign Hereditary Chorea Really Benign? Brain-Lung-Thyroid Syndrome Caused by NKX2-1 Mutations.

Authors:  Mered Parnes; Hassaan Bashir; Joseph Jankovic
Journal:  Mov Disord Clin Pract       Date:  2018-11-09

Review 2.  Current and Possible Future Therapeutic Options for Huntington's Disease.

Authors:  Mackenzie W Ferguson; Connor J Kennedy; Thulani H Palpagama; Henry J Waldvogel; Richard L M Faull; Andrea Kwakowsky
Journal:  J Cent Nerv Syst Dis       Date:  2022-05-21

Review 3.  The Many Faces of Huntington's Chorea Treatment: The Impact of Sudden Withdrawal of Tiapride after 40 Years of Use and a Systematic Review.

Authors:  Stephanie Feleus; Malu van Schaijk; Raymund A C Roos; Susanne T de Bot
Journal:  J Pers Med       Date:  2022-04-06

Review 4.  Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors.

Authors:  Nicki Niemann; Joseph Jankovic
Journal:  Drugs       Date:  2018-04       Impact factor: 9.546

5.  Pridopidine for the Improvement of Motor Function in Patients With Huntington's Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Authors:  Shujun Chen; Tianyu Liang; Tao Xue; Shouru Xue; Qun Xue
Journal:  Front Neurol       Date:  2021-05-13       Impact factor: 4.003

6.  Pharmacokinetics of Deutetrabenazine and Tetrabenazine: Dose Proportionality and Food Effect.

Authors:  Frank Schneider; David Stamler; Margaret Bradbury; Pippa S Loupe; Edward Hellriegel; Donna S Cox; Juha-Matti Savola; Mark Forrest Gordon; Laura Rabinovich-Guilatt
Journal:  Clin Pharmacol Drug Dev       Date:  2020-10-10

7.  Levodopa-Responsive Chorea: A Review.

Authors:  Mark Farrenburg; Harsh V Gupta
Journal:  Ann Indian Acad Neurol       Date:  2020-02-25       Impact factor: 1.383

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.